about
Brain metabolism in patients with schizophrenia before and after acute neuroleptic administrationImaging addiction with PET: is insight in sight?Functional magnetic resonance imaging of human brain activity in a verbal fluency task.Proton magnetic resonance of vitamin B 12 derivatives. Functioning of B 12 coenzymes.Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjectsGamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanismRacemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference.A Novel Strategy for Attenuating Opioid Withdrawal in Neonates.Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.Positron emission tomographic studies of aging and Alzheimer disease.Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats.Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission.Opioid receptor imaging and displacement studies with [6-O-[11C] methyl]buprenorphine in baboon brain.Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography.Limitations of brain imaging in forensic psychiatry.Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine.Subchronic racemic gamma vinyl-GABA produces weight loss in Sprague Dawley and Zucker fatty rats.Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents.Correlation of qEEG with PET in schizophrenia.Low cerebellar metabolism in medicated patients with chronic schizophrenia.Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.Correlation of PET and qEEG in normal subjects.Labeled putrescine as a probe in brain tumors.Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain.Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study.The brain and behavior: limitations in the legal use of functional magnetic resonance imaging.Diminished cerebral metabolic response to motor stimulation in schizophrenics: a PET study.Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results.The metabolic centroid method for PET brain image analysis.Positron emission tomography and computed tomography assessments of the aging human brain.Patterns of metabolic activity in the treatment of schizophrenia.Positron emission tomography studies of normal aging: a replication of PET III and 18-FDG using PET VI and 11-CDGPrevention of nitroprusside-induced cyanide toxicity with hydroxocobalaminSubcellular distribution of methylmalonyl CoA carbonylmutase in human liver extractsDopamine receptor occupancy and plasma haloperidol levels
P50
Q33622735-9B8A9D38-CC62-41F5-A1A7-0822B10690D4Q36101368-2FF98FAD-ADAB-42A3-91FC-B4FE6000A585Q36318034-C45AB70D-1239-4520-B82A-3B61F4134BB4Q36518332-9D2717B2-3C8C-47AA-B231-A0880FA21FFCQ36728072-6ED612D8-9B62-4F3D-8812-4ED8E7AEA04BQ36952331-0E837182-DB9C-4BAF-BD5E-C0B022281A86Q37216876-0B37B3AE-88FE-4C68-843A-B5F1F0BFE186Q37574445-11CFF5F7-B5B9-43A9-B398-930DB19FAE3FQ39895519-3BB3C8E5-3383-49A0-829E-BBBFF3912579Q41446119-B5E49BEF-437F-4D67-8383-14D5DD9E6314Q43629682-F0C23AD2-4CD8-4B9C-A4EC-1CECC1E66BA1Q43691705-7F17D124-5526-4EA6-96BE-017E3B4A7384Q43781210-E5BC3045-681F-4DC5-964F-A8D2FD933822Q44342634-47920F3F-C1F3-4CD5-930D-FEA8F931520CQ44344766-AEB130BE-00B2-4702-9BE1-18EC8E725DA7Q44474955-7F8CBE0E-CDE6-4EC4-A599-5968BE244C32Q44485031-BEA71DEF-F7C6-4546-AC8D-FDEB2FDFA641Q44489489-983CCF17-1013-4CFD-B9FB-F90BF9691739Q44492888-8F5955F3-EB18-4279-BF78-20C861E652AEQ44600287-6F665296-6A48-4CC6-9BD5-14E90D320324Q45150566-63B58E2A-6D45-41C4-8ACD-8EA50A02BB0BQ46013929-BC426F03-FE1E-4A1B-A24B-F2903ED5D848Q48412040-2391F6F9-D4DE-4603-9821-3C7B273F54B3Q48486099-01A9D2BB-1CD5-4F4C-BACC-C2253FFD2C10Q48510719-C4A3FEAE-A28B-4591-A0C1-F3C0A2B3A39CQ48577159-05A8AFE4-6389-4498-A167-695419D8148AQ48589381-FCFB915A-F50C-4F4F-A55C-08A8206F649BQ48761211-940A84E4-F191-4AD3-97E2-6EE366E58116Q49050186-28A4988B-EF1C-4DC1-AD1E-17B5732D0EA6Q51409779-683317C6-C6A3-4AB0-B65F-3BFE7A7D9515Q51898721-BF679F2E-5058-4DE0-AC59-109371FADA66Q52030953-3EBC701A-1B4C-48AA-856A-AB524EA7A911Q52289972-7C6E7BB3-B3F7-40CB-84FB-65761E06ED0DQ52531821-1922819F-6C7A-4CEF-8F3C-8FED78D3B6B7Q53197850-DB52C250-5A74-41AB-A886-F4BE4F96375EQ53784242-F2F7B12E-BBDB-4541-96EA-3E47C4EEFAEAQ57279022-116D86ED-B423-40E3-A817-71CBD29CC1EAQ67302021-93170C80-27A0-45AE-BA92-4909BA66DE0CQ68671607-C069A68E-713E-4053-B3B0-1D2B6A55A7FEQ69738004-5A55BFE0-D83E-4D36-B556-231874FF85A2
P50
description
researcher ORCID ID = 0000-0002-2254-8654
@en
name
Jonathan D Brodie
@ast
Jonathan D Brodie
@en
Jonathan D Brodie
@es
Jonathan D Brodie
@nl
type
label
Jonathan D Brodie
@ast
Jonathan D Brodie
@en
Jonathan D Brodie
@es
Jonathan D Brodie
@nl
prefLabel
Jonathan D Brodie
@ast
Jonathan D Brodie
@en
Jonathan D Brodie
@es
Jonathan D Brodie
@nl
P21
P31
P496
0000-0002-2254-8654